RxDoctor Payments Data

Karen Blitz Shabbir, DO

Neurology · Brooklyn, NYNPI 1275562894

Payments from drug & device makers

$240,573in general payments, 2019–2025

Across 492 payments — averaging $488.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$151K
  • Bristol Myers Squibb$32K
  • Genentech USA, Inc.$21K
  • AstraZeneca$20K
  • EMD Serono, Inc.$10K
  • E.r. Squibb & Sons, L.L.C.$5K
  • plus $3K from 22 others

What the payments were for

  • Consulting fees$38,25817%
  • Speaking & faculty fees$149,14768%
  • Travel & lodging$17,8548%
  • Food & beverage$14,6697%
  • Education$5070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$240,573 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$63,078
Medicare patients
278
Services billed
454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a21$189,689
Dalfampridine ErDalfampridine11$5,130
Gabapentin105$900
Quetiapine Fumarate31$895
Donepezil Hcl89$635
Levetiracetam21$489
Duloxetine Hcl24$480
Baclofen27$445
Nortriptyline Hcl24$348
Escitalopram Oxalate29$281
Pregabalin16$268
AmantadineAmantadine Hcl11$169
Tizanidine Hcl12$110
Trazodone Hcl22$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$150,876$189,68921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →